Show simple item record

dc.contributor.authorAuthorAlegría-Arcos, Melissa.
dc.contributor.authorAuthorBarbosa, Tábata
dc.contributor.authorAuthorSepúlveda, Felipe
dc.contributor.authorAuthorCombariza, German
dc.contributor.authorAuthorGonzález, Janneth
dc.contributor.authorAuthorGil, Carmen
dc.contributor.authorAuthorMartínez, Ana
dc.contributor.authorAuthorRamírez, David
dc.date.accessionedDate Accessioned2024-09-03T19:17:48Z
dc.date.availableDate Available2024-09-03T19:17:48Z
dc.date.issuedDate Issued2022
dc.identifier.citationReferencia BibliográficaFrontiers in Pharmacology, 13, 11 p.
dc.identifier.issnISSN1663-9812
dc.identifier.uriURIhttp://repositorio.udla.cl/xmlui/handle/udla/1368
dc.identifier.uriURIhttps://www.frontiersin.org/journals/pharmacology
dc.description.abstractAbstractThe coronavirus disease 2019 pandemic accelerated drug/vaccine development processes, integrating scientists all over the globe to create therapeutic alternatives against this virus. In this work, we have collected information regarding proteins from SARS-CoV-2 and humans and how these proteins interact. We have also collected information from public databases on protein–drug interactions. We represent this data as networks that allow us to gain insights into protein–protein interactions between both organisms. With the collected data, we have obtained statistical metrics of the networks. This data analysis has allowed us to find relevant information on which proteins and drugs are the most relevant from the network pharmacology perspective. This method not only allows us to focus on viral proteins as the main targets for COVID-19 but also reveals that some human proteins could be also important in drug repurposing campaigns. As a result of the analysis of the SARS-CoV-2–human interactome, we have identified some old drugs, such as disulfiram, auranofin, gefitinib, suloctidil, and bromhexine as potential therapies for the treatment of COVID-19 deciphering their potential complex mechanism of action.
dc.format.extentdc.format.extent11 páginas
dc.format.extentdc.format.extent2.643Mb
dc.format.mimetypedc.format.mimetypePDF
dc.language.isoLanguage ISOeng
dc.publisherPublisherFrontiers Media
dc.rightsRightsCreative Commons Attribution License (CC BY)
dc.sourceSourcesFrontiers in Pharmacology
dc.subjectSubjectDrug repurposing
dc.subjectSubjectNetwork pharmacology
dc.subjectSubjectProtein–drug interaction network
dc.subjectSubjectProtein–protein interaction network
dc.subjectSubjectSARS-CoV-2
dc.subject.lcshdc.subject.lcshCOVID-19 (Enfermedad)
dc.subject.lcshdc.subject.lcshPolypharmacology
dc.titleTitleNetwork pharmacology reveals multitarget mechanism of action of drugs to be repurposed for COVID-19
dc.typeDocument TypeArtículo
dc.udla.catalogadordc.udla.catalogadorCBM
dc.udla.indexdc.udla.indexWoS
dc.udla.indexdc.udla.indexScience Citation Index Expanded
dc.udla.indexdc.udla.indexScopus
dc.udla.indexdc.udla.indexDOAJ
dc.udla.indexdc.udla.indexBIOSIS
dc.udla.indexdc.udla.indexCAB Abstracts
dc.udla.indexdc.udla.indexEMBASE
dc.identifier.doidc.identifier.doi10.3389/fphar.2022.952192
dc.facultaddc.facultadFacultad de Ingeniería y Negocios


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record